22.03.2022 | Tracker

Respiratory Tracker: UK HCPs welcome new Asthma and Lung UK charity and highlight unmet needs

By Mark Sullivan

Each month, CREATION.co’s respiratory tracking update brings you the latest insights into the online UK healthcare professional (HCP) conversation regarding respiratory disease.

The conversation level of UK HCPs discussing respiratory disease on Twitter

From 21 February to 20 March 2022, the UK HCP respiratory disease online conversation consisted of 2,248 posts. These were authored by 1,147 HCPs, a decrease in both figures from January to February. Once again the mentions of COVID-19 online by UK HCPs diminished, with only 411 total mentions of the pandemic causing illness. Whilst the average number of online posts for UK HCPs discussing respiratory diseases was 1.96, physiotherapist Anne Bruton posted 26 times about the therapy area, making her this month’s most active UK HCP in the respiratory disease online space.

Image of a graph showing mentions over respiratory disease on Twitter

28 February saw the most respiratory disease online posts from UK HCPs this month. A large cause of this was HCPs responding to  data analysis findings from the new national charity Asthma and Lung UK, which found that only Turkey has a higher respiratory death rate than the UK, the death rate in Turkey is 162.7 per 100,000 people and 134.5 in the UK. Some shared the sentiment that air pollution is a major contributing factor to these findings, whilst others discussed the impact that images in mainstream media can have on patient education.

HCPs, as well as charities, responded positively to the news of Asthma and Lung UK’s launch, with many pointing to the alarming statistics surrounding lung disease within the UK and the potential beneficial changes the charity could bring about. Awareness of the launch was high amongst UK HCPs who mentioned the charity 99 times on Twitter throughout the month, many of these bringing challenges which the charity can tackle.

The most shared post of the month by UK HCPs in the context of respiratory disease, was from chest physician Nawar Bakerly who discussed the negative impacts that Ventolin inhalers have on the environment. This post was shared by over 35 fellow UK HCPs throughout the month and HCPs agreed with the sentiment that green powder inhalers are the future of treatment. HCPs this month also discussed how to choose the optimal inhaler for people with COPD and this focus from HCPs around environmental factors could be an integral part of the future treatment landscape for respiratory disorders.   

Each month, we track the HCP conversation relating to respiratory disease.

You can keep up to date with this and other pharmaceutical tracking updates, including COVID-19 developments, within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

If you would like to dig deeper into what we have seen this month then please do get in touch.


  • This article analysed the Twitter conversations of HCPs in the UK discussing respiratory disease and related terms between 21 February and 20 March 2022 using CREATION Pinpoint®.
  • Between 21 February and 20 March 2022, there were 2,248 UK HCP mentions of respiratory disease and related terms, from 1,147 unique UK HCP authors.

View the latest and archived respiratory trackers here

View all articles >

Meet the Author

Mark Sullivan

Mark uses his passion for data analysis to find actionable insights to inform pharma teams' strategic decisions.

Mark is an avid sports fan whether watching or playing. He enjoys spending time with his family and friends and watching films.

Suggested next

18.12.2020 | Article

UK HCPs engage with new COVID-19 respiratory support guidance from BTS and ICS

Discover what healthcare professionals (HCPs) think about respiratory disease

By Laura Marsh

02.11.2020 | Article

Top 50 Pharma Tracker: Regeneron tops list due to high profile COVID-19 treatment conversation

Discover what healthcare professionals (HCPs) think about Top 50 pharmaceutical companies

By Mary Kangley

View all articles >